Republic Healthcare Limited (Stock Code: 08357) has alerted shareholders that it expects its unaudited consolidated net loss for the year ended 31 December 2025 to increase by approximately S$3.70 million versus the prior-year period.

The Board attributes the deterioration to four main factors:

1. Revenue contraction: Intensified market competition, including the entry of new operators and aggressive expansion by existing rivals, has diverted part of the Group’s patient base and suppressed top-line performance.

2. Macroeconomic headwinds: Tariff adjustments and broader economic uncertainty have heightened patient price sensitivity, weighing further on revenue.

3. Regulatory cost burdens: Recent healthcare rule changes have lifted compliance expenses and operational complexity.

4. Rising operating expenses: • Foreign-exchange losses arose from a sharp depreciation of the US dollar and Hong Kong dollar against the Singapore dollar, the Group’s functional currency. • Start-up spending increased for the Group’s new education venture in the Philippines and its medical-service expansion in mainland China; both initiatives remain in early investment stages and have yet to generate meaningful revenue.

Full unaudited results for FY2025 are scheduled for release on 26 March 2026. Investors are advised to exercise caution when dealing in the company’s securities.